Hosted on MSN
Morgan Stanley upgrades DexCom (DXCM), cites undervalued recovery and G7 margin potential
DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, which was up from ...
ViCentra told customers that it expects no immediate impact from Dexcom's planned discontinuation of the G6 CGM line.
In his inaugural J.P. Morgan Healthcare Conference speech, newly minted Dexcom CEO Jake Leach looked to ease concerns over last year's supply shortage of the company's leading diabetes product. Leach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results